Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, Kragh Jørgensen RR, El-Galaly TC, Riise J, Leppä S, Christensen JH, Sonnevi K, Pedersen LB, Wader KF, Glimelius I. Jerkeman M, et al. Among authors: leppa s. Blood Adv. 2024 Jan 23;8(2):407-415. doi: 10.1182/bloodadvances.2023011920. Blood Adv. 2024. PMID: 38113470 Free PMC article. Clinical Trial.
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas.
Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S. Arffman M, et al. Among authors: leppa s. Med. 2024 Jun 14;5(6):583-602.e5. doi: 10.1016/j.medj.2024.03.007. Epub 2024 Apr 4. Med. 2024. PMID: 38579729 Free article. Clinical Trial.
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.
Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandarić L, Karjalainen-Lindsberg ML, Hyytiäinen M, Varjosalo M, Myklebust JH, Leppä S. Meriranta L, et al. Among authors: leppa s. Blood Cancer Discov. 2024 Sep 3;5(5):331-352. doi: 10.1158/2643-3230.BCD-23-0182. Blood Cancer Discov. 2024. PMID: 38630892
Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model.
Monzo HJ, Kalander K, Hyytiäinen MM, Elbasani E, Wall J, Moyano-Galceran L, Tanjore Ramanathan J, Jukonen J, Laakkonen P, Ristimäki A, Carlson JW, Lehti K, Salehi S, Puolakkainen P, Haglund C, Seppänen H, Leppä S, Ojala PM. Monzo HJ, et al. Among authors: leppa s. Mol Cancer Ther. 2023 Nov 1;22(11):1319-1331. doi: 10.1158/1535-7163.MCT-23-0008. Mol Cancer Ther. 2023. PMID: 37486980
Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma VM, Enblad G, Karjalainen-Lindsberg ML, Leppä S. Nyman H, et al. Among authors: leppa s. Bone Marrow Transplant. 2008 Jul;42(2):93-8. doi: 10.1038/bmt.2008.92. Epub 2008 Apr 7. Bone Marrow Transplant. 2008. PMID: 18391989
138 results